Literature DB >> 9720750

A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation.

A J Peniket1, A R Perry, C D Williams, A MacMillan, M J Watts, P G Isaacson, A H Goldstone, D C Linch.   

Abstract

A fatal case of EBV-associated lymphoproliferative disorder arising after a CD34-selected autologous peripheral blood stem cell transplant is reported in a patient with multiple myeloma in first plateau phase. It is suggested that this is likely to be a consequence of the accessory cell depletion associated with the CD34+ cell purification and it is recommended that a source of autologous T cells is stored before transplantation to be used if a severe opportunistic infection or EBV lymphoma arises post-transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720750     DOI: 10.1038/sj.bmt.1701335

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

Review 1.  Stem cell transplantation for autoimmune diseases.

Authors:  J Moore; P Brooks
Journal:  Springer Semin Immunopathol       Date:  2001

2.  CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications.

Authors:  S Maeda; Y Kagami; M Ogura; H Taji; R Suzuki; E Kondo; S Asakura; T Takeuchi; K Miura; M Ando; S Nakamura; T Ito; T Kinoshita; R Ueda; Y Morishima
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

3.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

4.  Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma.

Authors:  Sakura Izumiya; Mitsuaki Ishida; Keiko Hodohara; Takashi Yoshida; Hidetoshi Okabe
Journal:  Oncol Lett       Date:  2012-04-03       Impact factor: 2.967

5.  Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Authors:  Richard A Nash; Roger Dansey; Jan Storek; George E Georges; James D Bowen; Leona A Holmberg; George H Kraft; Maureen D Mayes; Kevin T McDonagh; Chien-Shing Chen; John Dipersio; C Fred Lemaistre; Steven Pavletic; Keith M Sullivan; Julie Sunderhaus; Daniel E Furst; Peter A McSweeney
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

6.  High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Authors:  Richard A Nash; James D Bowen; Peter A McSweeney; Steven Z Pavletic; Kenneth R Maravilla; Man-soo Park; Jan Storek; Keith M Sullivan; Jinan Al-Omaishi; John R Corboy; John DiPersio; George E Georges; Theodore A Gooley; Leona A Holmberg; C Fred LeMaistre; Kate Ryan; Harry Openshaw; Julie Sunderhaus; Rainer Storb; Joseph Zunt; George H Kraft
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

7.  Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma.

Authors:  Alberto Zambelli; Daniele Lilleri; Fausto Baldanti; Mario Scelsi; Laura Villani; Gian Antonio Da Prada
Journal:  BMC Cancer       Date:  2005-08-23       Impact factor: 4.430

8.  A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.

Authors:  A E Seif; A Naranjo; D L Baker; N J Bunin; M Kletzel; C S Kretschmar; J M Maris; P W McGrady; D von Allmen; S L Cohn; W B London; J R Park; L R Diller; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2013-01-21       Impact factor: 5.483

9.  An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.

Authors:  J L Powell; N J Bunin; C Callahan; R Aplenc; G Griffin; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2004-03       Impact factor: 5.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.